NIH Funded Study Has Targeted ALS and FTD Biomarkers
Researchers launched a multi-site project to identify early warning signs of neurodegenerative disease.
Updated on Oct. 5, 2026 in Alzheimer’s
Live Poll
Should medical research funding prioritize early disease detection over the development of later-stage treatments?
The University of Pennsylvania has launched a $26 million project funded by the National Institutes of Health to identify biomarkers for ALS and FTD. The study will track 330 participants carrying the C9orf72 gene variant to predict disease onset before symptoms appear.
Why it matters
Previous clinical trials for ALS and FTD have often failed because interventions began only after physical symptoms manifested. By establishing reliable biomarkers, researchers aim to enable earlier interventions through future preventive clinical trials.
The five-year study tracks 330 participants aged 45 and older who carry the C9orf72 gene variant. The project spans 14 research sites across the United States, utilizing cognitive testing, MRI scans, and body fluid analysis.
The players
University of Pennsylvania
This Ivy League research university serves as the lead institution for the national ALS and FTD biomarker project.
National Institutes of Health
This primary agency of the United States government is responsible for biomedical and public health research.
University of Miami
This Florida-based research institution is a key collaborator in tracking participants for the multi-site study.
The details
The research team will test five candidate biomarkers, both individually and in combination, to determine their accuracy in predicting disease onset. Participants will undergo regular motor and cognitive evaluations, along with advanced imaging and fluid testing throughout the five-year observation period.
Timeline
Participant enrollment for the study is scheduled to begin in December 2026.
The research project will continue over a five-year study period.
The Big Picture
This study follows the established research protocols surrounding the C9orf72 gene variant, which is known to cause increased risk for ALS and FTD. It represents a shift toward longitudinal pre-symptomatic data collection in neurodegenerative research.
This project aims to improve future treatment options by identifying patients at risk before they show clinical symptoms. Participants may benefit from advanced clinical monitoring during the five-year study duration.
The takeaway
Early detection remains the most significant hurdle in treating neurodegenerative conditions like ALS and FTD. Establishing a reliable biomarker pipeline could eventually lead to preventive therapies for high-risk genetic carriers.
What happens next
The research team plans to begin the enrollment process for all 330 study participants by December 2026.
Further reading
For more information on current research initiatives, visit the Alzheimer’s section.
Live Poll
Should medical research funding prioritize early disease detection over the development of later-stage treatments?
